Actinium Pharmaceuticals (Delaware) (ATNM) vs Veru (VERU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Veru (VERU) has outperformed Actinium Pharmaceuticals (Delaware) (ATNM) over the past year, losing 12.6% versus a loss of 21.1%. Over five years, ATNM leads with a -85.6% price change compared with -97.5% for VERU. Veru is the larger company by market cap ($33.1 million vs $33.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATNM | VERU |
|---|---|---|
| Share price | $1.05 | $1.94 |
| Market cap | $33.01M | $33.08M |
| 1-day change | -1.87% | -8.06% |
| YTD return | -22.79% | -9.35% |
| 1-year return | -21.05% | -12.61% |
| 5-year return | -85.60% | -97.50% |
| P/E ratio (TTM) | 2.44 | — |
| EPS (TTM) | $0.43 | $-0.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $90.00K | — |
| Net income (latest FY) | $-33.89M | $-22.73M |
| Operating margin | -40274.44% | — |
| Net margin | -37652.22% | — |
| 52-week high | $1.72 | $7.33 |
| 52-week low | $0.735 | $1.93 |
| Distance from 52-week high | -38.95% | -73.53% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +242.86% | +1223.20% |
| Average volume | 193.83K | 193.35K |
| Shares outstanding | 31.44M | 17.05M |
| Employees | 27 | 20 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Actinium Pharmaceuticals (Delaware)
ATNM stock →Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About Veru
VERU stock →Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
ATNM vs VERU FAQ
Which is bigger, Actinium Pharmaceuticals (Delaware) or Veru?
Veru (VERU) is larger, with a market capitalization of $33.08M compared with $33.01M for Actinium Pharmaceuticals (Delaware) (ATNM).
Which stock has performed better over the past year, ATNM or VERU?
VERU returned -12.61% over the past 12 months, compared with -21.05% for ATNM (price return, excluding dividends). Past performance does not predict future results.
Are Actinium Pharmaceuticals (Delaware) and Veru in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.